Annovis Bio, Inc. (ANVS)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $1.02
- As of
Kresmion compiles this page from ANVS's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Annovis Bio, Inc. (ANVS): 4 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-10-20.
See the full ANVS dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for ANVS on one page. Preview it with sample data, then open it live with a free account.
Preview the ANVS dossierActive events for ANVS
- high13F: funds added
4 tracked funds increased ANVS this 2026Q2, institutional consensus
- mediumEarnings above estimates
Q2-2026: Beat consensus by 13.5%, EPS $-0.40 vs $-0.4624 estimate
- high13F: funds added
3 tracked funds increased ANVS this 2026Q2, institutional consensus
- high13F: large increase
CITADEL ADVISORS LLC added +241% to ANVS (2026Q2)
- high13F: large increase
CITADEL ADVISORS LLC added +165% to ANVS (2026Q2)
FREE, NO ACCOUNT
Every event on ANVS, as it fires
You are seeing 5 of 10 events recorded on ANVS since 2026-07-24.
The five above landed across 3 days. The other 5 were recorded on 2 other days. 6 of the 10 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in ANVS (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLCCUSIP 03615A108 · 2026Q2 | $1.9M | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 03615A108 · 2026Q2 | $1.1M | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP 03615A108 · 2026Q2 | $453K | 0.00% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 03615A108 · 2026Q2 | $44K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, ANVS
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
ANVS against its peers
ANVS's return on equity of -171.2% ranks in the 25th percentile of 21 Biotechnology sub-industry peers, fiscal periods ending between 2025-06-30 and 2026-06-30.
| Metric | ANVS | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 0.0 USD | 100000 USD | 8 | 11 |
| Operating margin | n/a | -19009.2% | n/a | 10 |
| Net margin | n/a | -16194.9% | n/a | 10 |
| Return on equity | -171.2% | -76.5% | 25 | 21 |
Peers (24): GRDX, INMB, SER, KLRS, ATHE, HYPD, ESLA, ALDX, ATNM, GRCE, MREO, VERU, BMEA, TIL, DWTX, EDSA, NNVC, IMA, ACET, CNTB, IBIO, LONA, SGMOQ, EXOZ. Left out: HSTC (period gap). Fiscal periods ending between 2025-06-30 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (ANVS: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow ANVS on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to ANVS for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.